SCHEMBL19203603

SCHEMBL19203603

Cc1cc(F)c(C(C)(C)C)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
TP53 P04637 2/20 0.39
HIF1A Q16665 2/20 0.39
CD44 P16070 1/20 0.38
CYP1A2 P05177 2/20 0.33
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
GRIN3A Q8TCU5 1/20 0.32
ALDH1A1 P00352 4/20 0.32
POLB P06746 2/20 0.32
CA2 P00918 1/20 0.32
TYR P14679 1/20 0.32
LMNA P02545 1/20 0.31
CYP3A4 P08684 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701538 0.91 CD44 (0.38) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL15701548 0.84 SMN1; SMN2 (0.38) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL25036379 0.83 CD44 (0.38) CD44GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL19203492 0.83 SMN1; SMN2 (0.39) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL17083896 0.82 SMN1; SMN2 (0.37) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL16448479 0.82 SMN1; SMN2 (0.37) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL2756065 0.81 CYP1A2 (0.38) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL19198900 0.79 SMN1; SMN2 (0.42) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL30843769 0.79 SMN1; SMN2 (0.42) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A
SCHEMBL9074167 0.79 SMN1; SMN2 (0.42) SMN1; SMN2CYP2C9CYP2C19TP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
WO-2017132173-A1 MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE REGENERON PHARMACEUTICALS, INC. (US) 2017-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, P2RX3 SMN1; SMN2 1218/4885CYP2C9 640/4885CYP2C19 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.